Pathological response was evaluated in 13 pts, 1 pt was additionally treated by preoperative locoregional radiotherapy, 1 pt continue the treatment.

pCR = 9/13 pts (69.2%) − complete disappearance tumor in the breast and lymph nodes occurred in 8 pts (61.5%) and 1 pt (7.6%) had pCR + in situ (in situ lesions only in breast tissue).

Toxicity was assessed for 75 treatment cycles. Grade III–IV neutropenia was observed in 76% of cycles. Febrile neutropenia was observed in 14.7% of cycles, no intravenous antibacterial therapy was required. Grade I−II transaminase increase and/or bilirubin was recorded in 29.3% of cycles; grade II mucositis − 10.7%. Only 1 pt had asymptomatic LVEF decrease on 10%.

Conclusion: the combination of Docetaxel 75 mg/m^2 + Carboplatin AUC 5 + Trastuzumab every 3 weeks is promissing regimen (pCR − 69.2%) with manageable toxicity for treatment of locally advanced HER-2 overexpression breast cancer.

Wednesday, 24 March 2010 18:15–19:15

POSTER SESSION

Predictive and prognostic factors

121 Poster

A prognostic model for breast cancer-related events in primary operated invasive lobular breast cancers from one centre

I. Dierickx[1], V. Van Belle[2], T. Vandorpe[2], H. Wildiers[1], K. Leunen[1], S. Peeters[1], P. Moerman[1], K. Deraedt[1], M. Christiaens[1], P. Neven[1]. [1]*U.Z. Gasthuisberg, Multidisciplinary Breast Centre, Leuven, Belgium;* [2]*KU Leuven, Electrical Engineering (ESAT), Leuven, Belgium*

Background: Invasive lobular breast cancers (ILA) differ from non-ILA in many perspectives. ILA are a heterogeneous group with a large variety in histologic subtypes and disease free survival (DFS); a prognostic model for ILA is not available. We propose a model based on demographic and clinicopathological features.

Material and Methods: A retrospective cohort study of 380 consecutive patients treated between Jan 2000 and Dec 2006 for primary operable ILA, none E-cadherin positive, and all receiving local and systemic adjuvant therapy (108/380 or 28.4% had chemotherapy). None received neo-adjuvant therapy and those with a bilateral or multifocal disease with the non-ILA having a higher NPI than the ILA were not in this cohort. We investigated independent demographic and clinic-pathological variables for relapse.

Results: After a mean follow-up of 5.3 yrs, 37 patients (9.7%) experienced a breast cancer-related event. In a univariate setting, variables considered as significant ($p < 0.05$) were: node positivity (np), tumor size, grade (1−2 vs 3), mitotic count (1 vs 2−3, mito), the amount of nuclear pleomorfism (1−2 vs 3, pleo) and subtype, classical ILA or not. The tubule formation was not considered as a variable since 98.4% of the patients had less than 10% of the tumor forming tubules. A multivariate Cox model revealed that np, nuclear atypia and mitotic count are independent prognostic factors. We propose to divide patients into risk groups as illustrated in Table 1. Patients in group 1 (node negative) are considered as low risk, patients in group 3 are high risk. Table 1 also describes the predicted (S_{COX}) and observed survival (S_{KM}).

Conclusions: Our prognostic model of operable ILA showed that nor histological grade or subtype nor nuclear atypia nor mitotic activity are prognostic in node negative ILA. In node positive ILA, the combination of nuclear atypia and mitotic index distinguished a medium and high risk group. Risk groups can be defined without the complex definition of classical ILA.

Table 1: Categorizing patients into risk groups

Nuclear atypia	Mitotic count	Node positive	Risk group	N$^+$	# events	Event rate*	S_{KM} (5-yr)	S_{COX} (5-yr)
1 of 2	1, 2 of 3	no	1					
3	1	no	1					
3	2 of 3	no	1	211	8	0.01	0.95	0.95
1 of 2	1, 2 of 3	yes	2	136	21	0.03	0.84	0.86
3	1	yes	2					
3	2 of 3	yes	3	29	8	0.07	0.68	0.62

[a]4 patients had no value for one or more model variables.
[b]Expected percentage of events per year of follow-up.

122 Poster

Bevacizumab combined with chemotherapy as first-line treatment of metastatic breast cancer patients: a meta-analysis based on studies having randomized 2,695 patients

J. Rossari[1], E. de Azambuja[1], O. Metzger[1], A. Gennari[2], M. Piccart-Gebhart[1], M. Paesmans[1]. [1]*Institut Jules Bordet, Medical Oncology, Brussels, Belgium;* [2]*Galliera Hospital, Medical Oncology, Genoa, Italy*

Background: Bevacizumab, a monoclonal antibody against VEGF, has been shown to improve the outcome of patients with metastatic breast cancer. We conducted a meta-analysis of randomized trials to assess the magnitude of the benefit of adding bevacizumab to chemotherapy in the first-line treatment of metastatic/recurrent breast cancer (MBC) in terms of progression-free and overall survival as well as tumour response rate. The commonest side-effects of bevacizumab were also evaluated.

Methods: Randomized phase III trials evaluating the addition of bevacizumab to chemotherapy for the first-line treatment of MBC were identified using PubMed and/or abstracts presented at major oncology meetings. Hazard Ratios (HR) for time-to event endpoints and odds ratios (OR) for binary endpoints were calculated or retrieved from each study and combined using the fixed-effects or random-effects whenever indicated.

Results: Three studies were selected with a total of 2,695 randomized patients; only one study was published in a peer review journal at the moment this meta-analysis was performed. The addition of bevacizumab to chemotherapy improved progression-free survival (PFS) (HR 0.69; 95% CI 0.63–0.76) and response rates (OR 1.84; 95% CI 1.56–2.18) in patients receiving the combination compared to chemotherapy alone. A trend towards better overall survival was also observed (HR 0.88; 95% CI 0.78–1.00). The benefit of adding bevacizumab to chemotherapy was observed in all subgroups (ER positive or negative, age <65 or $\geqslant$65, short or long disease-free interval, prior adjuvant chemotherapy, and prior taxanes). As expected, toxicity profile included hypertension, proteinuria, sensory neuropathy and left ventricular dysfunction, and was significantly more pronounced in patients receiving bevacizumab.

Conclusion: In our meta-analysis the addition of bevacizumab to chemotherapy in the first-line treatment of patients with MBC significantly improves PFS and response rates in all patient population and across different subgroups. A trend towards better overall survival was also observed. Side effects were more often observed in patients receiving bevacizumab.

123 Poster

Preoperative capecitabine and docetaxel followed by 5-FU/epirubicin/cyclophosphamide (FEC) and predictive value of protein biomarkers

H. Jinno[1], S. Matsuda[1], M. Takahashi[1], M. Sakata[1], T. Hayashida[1], M. Mukai[2], T. Ikeda[3], Y. Kitagawa[1]. [1]*Keio University School of Medicine, Surgery, Tokyo, Japan;* [2]*Keio University School of Medicine, Pathology, Tokyo, Japan;* [3]*Teikyo University School of Medicine, Surgery, Tokyo, Japan*

Background: Capecitabine (X) and docetaxel (T) have demonstrated synergistic effect in preclinical models and survival benefit in metastatic breast cancer. Useful predictive marker is necessary for breast cancer patients treated with preoperative chemotherapy. This study's purpose was to determine the efficacy of X and T followed by 5-FU/epirubicin/cyclophosphamide (FEC) in the preoperative setting and to evaluate the correlation between protein biomarker expression and pathological complete response (pCR).

Patients and Methods: Patients with stage II/III breast cancer received 4 cycles of XT (capecitabine 1650 mg/m^2 on days 1−14 and docetaxel 60 mg/m^2 on day 8 every 3 weeks), followed by 4 cycles of FEC (fluorouracil 500 mg/m^2, epirubicin 90 mg/m^2, cyclophosphamide 500 mg/m^2 on day 1 every 3 weeks). Primary endpoints were the pathological complete response (pCR) rate and adverse drug reactions. pCR was defined as no microscopic evidence of residual viable tumor cells, invasive or noninvasive, in all resected specimens of the breast. Expression analysis using immunohistochemistry was performed in core needle biopsy samples at baseline.

Results: Seventy-two patients were enrolled and 71 patients were assessable for clinical and pathologic responses. The median age was 51 years (range, 27−69 years). The median tumor size was 3.5 cm (range, 2−8.3 cm). Forty-six (64.8%) patients were clinically node-positive. Overall, 50 (50.1%) patients had hormonal receptor (HR)-positive tumors, and 21 (29.6%) had HR-negative tumors. A HER2 overexpression was detected in 19 cases (26.8%). Ki67 expression ranged from 0 to 92.3% and 34 cases showed 20% and higher of positive nuclei. The overall response rate was 91.5%, including a complete response in 29 patients and a partial response in 36 patients. No patients showed clinical progression of disease. The pCR rate was 14.1% (10/71). Grade 3/4 neutropenia was observed in 32.4%